# Single Ascending Dose Study of AMG 570 in Healthy Subjects

> **NCT02618967** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 56 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** AMG 570
- **BIOLOGICAL:** AMG 570 Matching Placebo

## Key facts

- **NCT ID:** NCT02618967
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-28
- **Primary completion:** 2018-09-06
- **Final completion:** 2018-12-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02618967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02618967, "Single Ascending Dose Study of AMG 570 in Healthy Subjects". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02618967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*